Exchange: NASDAQ·Updated 07:30 PM EDT

TNDM News

News
all
press releases
Tandem Diabetes Care to Announce Third Quarter 2026 Financial Results on November 5, 2026
Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a leading insulin delivery and diabetes technology company, plans to release its third quarter 2026 results after the financial markets close on Thursday, November 5, 2026. The Company will hold a conference call and simultaneous webcast on the same day at...
Business Wire
Tandem Diabetes Care to Announce Third Quarter 2026 Financial Results on November 5, 2026
Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a leading insulin delivery and diabetes technology company, plans to release its third quarter 2026 results after the financial markets close on Thursday, November 5, 2026. The Company will hold a conference call and simultaneous webcast on the same day at...
Business Wire
More News
Tandem Mobi Automated Insulin Delivery System Now Available in Twelve International Markets
Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced that Tandem Mobi, the worlds smallest, durable automated insulin delivery system for people living with diabetes,1 is now available in 12 countries outside the United States. The...
Business Wire
Tandem Diabetes Care (TNDM) Soars 7.7%: Is Further Upside Left in the Stock?
Tandem Diabetes Care (TNDM) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Zacks
Reasons to Retain Tandem Diabetes Stock in Your Portfolio Now
TNDM's expanding pump lineup and pay-as-you-go model support growth prospects, though macro and competitive pressures remain.
Zacks
Aging Population Drives Healthcare Growth: Stocks to Watch
AbbVie, Tandem Diabetes Care and Amgen are targeting aging-related healthcare growth through advances in immunology, diabetes and cardiovascular care.
Zacks
Can PODD Sustain Growth After Its 2026 Guidance Reset and Q2 Beat?
Insulet's Q2 beat and stronger margins contrast with a 2026 growth reset, putting U.S. Type 2 retention at the center of its outlook.
Zacks
Innovative Insulin Pumps Drive Optimism for Tandem, Beta Bionics
William Blair initiates coverage on Tandem Diabetes Care and Beta Bionics, highlighting their growth potential in the insulin pump market.read more...
Benzinga
TNDM Q2 Loss Narrower Than Expected, Revenues Miss, Stock Up
Tandem Diabetes shares jump 19.1% after a narrower-than-expected Q2 loss, as higher pump shipments and a 57% gross margin offset a slight revenue miss.
Zacks
Tandem Diabetes Care, Inc. (TNDM) Reports Q2 Loss, Lags Revenue Estimates
Tandem Diabetes Care (TNDM) delivered earnings and revenue surprises of +8.82% and -0.10%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Tandem Diabetes Care (TNDM) Reports Q2 Earnings: What Key Metrics Have to Say
Although the revenue and EPS for Tandem Diabetes Care (TNDM) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Zacks

Advertisement|Remove ads.